Psoriasis and Diabetes

Ermira Vasili, Migena Vargu, Genc Burazeri, Katerina Hysi, Elna Cano and Brikena Bezati
University Hospital Center “Mother Teresa”/ Dermatology-Venerology, Tirana, Albania

1. Introduction

The term "Diabetes mellitus" encompasses a heterogeneous group of disorders characterized by insulin hyposcretion and/or insensitivity. Type 1 DM is a chronic autoimmune disease associated with selective destruction of insulin-producing pancreatic b-cells. A variety of gene loci have been studied to determine their association with type 1 DM. The early studies suggested that the B8 and B15 of HLA class I antigens were increased in frequency in the diabetics compared to the control group. However, more recently the focus has shifted to the class II HLA-DR locus. It was found that DR3 and DR4 were more prevalent than HLA-B in type 1 DM than HLA-B. The nature of autoantigen(s) responsible for the induction of type 1 DM is unknown. The identification of autoantigens in type 1 DM is essential both for diagnostic purposes and for potential immunotherapeutic intervention in the disease process.

Type 2 DM has a greater genetic association than type 1 DM. The 100% concordance rate in identical twins is thought to be overestimated, due to a selection or reporting bias. A population based twin study in Finland has shown a concordance rate of 40%. Environmental effect may be a possible reason for the higher concordance rate for type 2 DM than for type 1 DM. Perturbations in glucose metabolism due to insulin resistance are further exacerbated when insulin production is compromised. Insulin resistance is a characteristic feature of most patients with Type 2 diabetes mellitus. Several cross-sectional studies in non diabetic subjects on the general population or in individuals with impaired glucose tolerance (IGT)/impaired fasting glucose (IFG) have confirmed that acute-phase reactants such as CRP (and sometimes the cytokines IL-6 and TNF-α) are positively correlated with measures of insulin resistance/plasma insulin concentration, BMI/waist circumference, and circulating triglyceride and negatively correlated with HDL cholesterol concentration. In general, increasing components of the metabolic syndrome in individuals are associated with higher levels of inflammatory markers.

In subjects with IGT or IFG, IL-6 but not TNF-α appears to be elevated compared with individuals with normal glucose tolerance and in one study, inflammatory markers were related to insulin resistance but not to insulin secretion.

Psoriasis is a chronic inflammatory disease of the skin, scalp, nails, and sometimes joints that affects 1-2 percent of the general population. Psoriasis is a clinical diagnosis. The disease is characterized by erythematous and indurate plaque which usually are covered by thick silvery white scales and can manifests as psoriatic arthritis (PsA), an inflammatory joint
disease resulting in extensive bone resorption and joint destruction. Although the clinical course of psoriasis is highly variable between individuals, the lesions are typically recurrent. The aim of this study is to define the linkage between psoriasis and diabetes. There has been performed a retrospective study (cross-sectional study). The data used in this study were obtained from the University Hospital Center “Mother Teresa” in Tirana. Being the only University Hospital Center, it admits as well patients from other districts of Albania. Clinical files of the patients from moderated to severe psoriasis, hospitalized in the dermatology clinic during the period 2000-2010, have been examined. Control group are been considered other hospitalized non psoriasis cases in this hospital center. Both groups had its glycemia values recorded. T-test (student test) was used to compare the continuous variables while the statistical analysis was performed by using SPSS software.

2. Genetics of psoriasis

Associations between psoriasis and particular HLA types have been recognized for nearly 30 years. Henseler and Christophers defined type I psoriasis as having age of onset younger than 40 years, with strong HLA associations. Patients with type II disease were characterized by age of onset 40 years or older, and much weaker HLA associations. Patients with type I disease showed a much stronger tendency for familial involvement. The risk ratio for first-degree relatives was approximately 10 for patients with type I psoriasis, but only about 1 to 2 for those with type II psoriasis. The HLA associations identified in the study of familial psoriasis by James T et al. are very similar to those identified in previous case-control studies of HLA association in psoriasis. In particular, strong associations with HLA-Cw6 and HLA-B57 were found. Approximately two thirds of the psoriatic patients in those earlier studies had a family history negative for psoriasis and could be assumed to represent sporadic cases. The similarity of the HLA associations obtained in pedigree and case-control studies implies that so-called sporadic psoriasis must also have a genetic basis. Because no other inflammatory disease manifests such a strong HLA-C association, it suspect that the MHC psoriasis gene is a disease-specific gene.

The study of Houglin Wang et al confirmed that a locus on chromosome 10, drives the development of psoriasiform skin disease as well as arthritis in the presence of low expression of the common chain of \( \beta_2 \) integrins (CD18). They show that a congenic strain containing the 9-cM PL/J element on chromosome 10 (D10mit126 to D10mit194), designated as chromosome 10B PSD1 congenic strain, on the resistant C57BL/6J CD18hypo background developed psoriasiform skin disease, and most notably also a severe arthritis of joints. The PL/J background in the presence of low CD18 expression drives the development of psoriasiform skin disease but rarely in combination with arthritis.

In contrast, the two produced congenic strains harboring fragments telomeric and centromeric of the 9-cM PSD1 fragment (chromosomes 10A and 10D) did not develop the psoriasiform skin disease and/or arthritis within an observation period of 10 mo. These data indicate that a gene (or genes) within the PSD1 locus contribute(s) to pathogenic events common to the psoriasiform skin disease and arthritis in this context under the condition of low expression of CD18.

Since the chromosome 10C mice, congenic for a larger fragment of the chromosome 10 including the PSD1 locus, developed a phenotype identical to the PSD1 congenic (chromosome 10B), they conclude that the PSD1 locus is the major locus within that region.
It is estimated that approximately 40% of individuals suffering from psoriasis or psoriatic arthritis (PsA) have a first-degree relative who has the disease. In addition, concordance rates as high as 70% have been reported among identical twins. Given the strong genetic component of psoriasis, patients who have psoriasis are often concerned about the heritability of the disease. Family studies indicate that if both parents have psoriasis then the offspring have a 50% chance of developing the disease; if only one parent has psoriasis then the risk for a child to develop psoriasis is 16%. If neither parent is affected but a child develops psoriasis then his/her siblings have an 8% risk for developing the disease. Men have a higher risk for transmitting psoriasis to offspring than women, likely because of genomic imprinting, which is an epigenetic effect that causes differential expression of a gene depending on the gender of the transmitting parent. Because genetics are immutable, modifiable environmental risk factors for psoriasis are of special interest. Further efforts to identify the long-sought gene/genes involving in the pathogenesis of psoriasis continue.

3. Risk factors

There are several risk factors that may provide the environmental stimulus for T-cell proliferation leading to the development of psoriasis. They include psychological stress, certain medication such as antimalarial drugs, beta blockers, lithium and non-steroidal, anti-inflammatory drugs, a history of skin infection, obesity, smoking and alcohol consumption.

3.1 Stressful like events (psychological stress)

The recognition of psychological needs in patients with psoriasis is critical for managing the condition. Psoriasis can have a substantial psychological and emotional impact on an individual, which is not always related to the extent of skin disease. There are elevated rates of various psychopathologies among patients with psoriasis including poor self-esteem, sexual dysfunction, anxiety, depression, and suicidal ideation. In different studies (most of them are retrospective) from about one third to about three fourth of psoriatics believed that there was a stress worsening of their psoriasis. The results of an other study do not indicate a major significance of stress for plaque psoriasis patients. But this was a small study. The clinical severity of psoriasis may not reflect the degree of emotional impact of the disease. Still it cannot be ruled out that stress may be an important factor for some psoriasis patients.

3.2 Smoking

An increased prevalence of smoking among patients with psoriasis has been observed in numerous countries including Finland, Italy, the United Kingdom, Norway, China, and the United States. Cigarette smoking has been shown to correlate with increased disease severity and increased mortality in causes of death related to smoking in patients with psoriasis. In a study, 35 patients who smoked more than 10 cigarettes per day had more severe psoriasis affecting both forearms, hands and feet compared with non-smokers (all P<0.05). Studies have proposed different mechanisms that could link nicotine to psoriasis, including the enhancement of pro-inflammatory cytokines and altered morphology and functionality of leukocytes.
3.3 Alcohol consumption

Multiple studies have shown that increased alcohol use, and in some cases, abuse, are independent risk factors for psoriasis. A positive dose-response relationship between alcohol intake and psoriasis severity in women was seen in one prospective questionnaire-based study.

Several studies have evaluated the link between psoriasis and alcoholism. However, further study is needed to determine whether an increase in alcohol consumption is a primary risk factor for the development of psoriasis or whether alcohol abuse is a secondary factor related to psychosocial rejection that some psoriasis patients may experience.

3.4 Obesity

Over the last decade, studies showed a chronic condition of mild inflammation caused by obesity, with high levels of TNF-α, IL-6, and C-reactive protein associated with an increase of BMI. Obesity could play a role in the development of psoriasis, based on the pro-inflammatory state it provokes. Or perhaps it could be a consequence of psoriasis, caused by metabolic deregulations induced by the pro-inflammatory state, associated with a poor quality of life and inadequate food habits of the disease carrier.

3.5 Medication

Psoriasis and psoriasiform eruptions have also been associated with use of other antihypertensive such as angiotensin II (AT II) antagonists, calcium channel blockers (CCBs) or clonidine.

Beta-blockers and ACE inhibitors are widely used drugs for the treatment of hypertension, a disease which has been associated with psoriasis, but there is no consensus on the mechanism by which beta-blockers might induce such a reaction.

3.6 Infections

Microorganisms have been associated to the development of psoriasis. β-hemolytic streptococcal infections are linked to the development of guttate psoriasis and intercurrent infections have been associated to pustular psoriasis flares. Streptococcal antigens have been reported, suggesting an autoimmune component in the disease. Protective immunity against streptococci is therefore likely to be dependent on both CD4+ and CD8+ T cells. It is of interest, in this context, that both CD4+ and CD8+ T cells isolated from psoriatic skin lesions have been shown to be respond to crude streptococcal antigens.

4. Immunopathogenesis of psoriasis

Despite its unknown etiology, there have been break throughs in the understanding of the immunopathogenesis of psoriasis in recent years. It is now almost certain that psoriasis is a T-lymphocyte mediated inflammatory dermatosis with hyper-proliferation of keratinocytes in genetically predisposed subjects.

At the cellular level, psoriasis is characterized by markedly increased epidermal proliferation and incomplete differentiation; elongation, dilatation and “leakiness” of the superficial plexus of dermal capillaries; and a mixed inflammatory and immune cell infiltrate of the epidermis and papillary dermis.

It is now believed that the clinical phenotype of psoriatic skin arises from the interplay between inflammatory cytokines and cells that make up the cutaneous microenvironment (ie, lymphocytes, antigen-presenting cells [APCs], endothelial cells, and keratinocytes).
Th1 lymphocytes have been identified as a primary source of inflammatory cytokine production in psoriatic skin; regulatory T cells, which normally suppress effector T-cell activity, are dysfunctional in the blood and skin of patients who have psoriasis; and recently identified Th17 cells produce the cytokine interleukin (IL)-17, which is critical to the establishment and maintenance of autoimmunity, and IL-22, which is primarily involved in the process of epidermal differentiation and hyperproliferation. APCs (ie, plasmacytoid and myeloid dendritic cells) and endothelial cells lining the dermal microvasculature have also been shown to play a role in psoriatic disease. In particular, dermal dendritic cells have been shown to contribute to the production of Th1 cytokines (such as IFN-α, TNF-α and IL-2) and the recruitment of inflammatory cells into psoriatic plaques. The production of IL-20 and IL-23 by myeloid dendritic cells has been reported to promote keratinocyte proliferation, up-regulate inflammatory gene products, and stimulate T-cell activation, all of which contribute to psoriatic lesions. Endothelial cells play a critical role in recruiting inflammatory cells through their expression of E-selectin, which enhances the homing of cutaneous lymphocyte-associated antigen-positive T cells into the skin. Angiogenesis is stimulated by the inflammatory process and studies demonstrate that circulating levels of vascular endothelial growth factor correlate with psoriasis activity.

5. Psoriasis and comorbidities

The multiaspect nature of psoriasis as a systemic disease associated with numerous multiorgan abnormalities and complications has been recognized. Many epidemiologic studies with varies designs link psoriasis to systemic metabolic comorbidities. Psoriasis and its comorbidities share a common etiological linkage, it is hypothesized that proinflammatory cytokines contribute to dyslipidemias, atherogenesis, peripheral insulin resistance, type II diabetes, hypertension etc.

5.1 Cardiovascular risk in patients with psoriasis

Several studies have demonstrated that cardiovascular diseases and their associated risk factors are more common in patients with psoriasis than in the general population. The cause of this elevated risk is unclear. Severe psoriasis is associated with an increased prevalence of metabolic syndrome. Metabolic syndrome is generally defined by the presence of or treatment for at least three of the following five criteria: hypertension, insulin resistance, decreased high-density lipoprotein, hypertriglyceridemia, and central obesity. Mallbris et al. performed a historical cohort study to assess the risk for cardiovascular mortality among psoriasis patients. These data suggest on the one side, that psoriasis patients with more severe disease have a substantially increased risk for cardiovascular death. On the other side, it can be argued that the available in-hospital treatment modalities contribute to this risk as well. The increased risk of MI and vaso-occlusive disease was attributed to the increased prevalence of risk factors in psoriatic patients including lifestyle factors such as smoking and alcohol abuse. Evolving research suggests that the chronic inflammatory nature of psoriasis itself may lead to adverse health outcomes, including coronary artery disease and myocardial infarction (MI).

Several cytokines that have been identified as important mediators of psoriasis, such as interleukins 1, 4, 6, 8, 12 and tumor necrosis factor-α, have also been identified in metabolic syndrome, a chronic inflammatory state associated with obesity. Given the link between atherosclerosis and inflammation, the risk of cardiovascular disease is likely to be increased in patients with psoriasis.
Psoriasis and atherosclerosis may have certain common underlying pathogenic mechanisms. A separate prospective study demonstrated an increased relative risk for myocardial infarction compared to healthy controls; this increased risk was greater in younger patients with mild or severe psoriasis, compared to older patients with similar severity of disease.

Epidemiologic studies show that atherosclerosis has a number of causal risk factors, several of which (cigarette smoking, atherogenic lipids, hypertension, and hyperglycemia) involve cytokines, other bioactive substances, and cells characteristic of the inflammatory process.

Gelfand JM, et al., had conducted a population-based cohort study using data collected by general practitioners participating in the General Practice Research Database in the United Kingdom from 1987-2002. A total of 556,995 control patients and patients with mild (n = 127,139) and severe psoriasis (n = 3,837) were studied, and controlled for traditional cardiovascular risk factors (diabetes mellitus, history of myocardial infarction (MI), hypertension, hyperlipidaemia, smoking). They found that the adjusted relative risks of MI are 1.54 (1.24–1.91) and 7.08 (3.06-16.36) respectively in mild and severe psoriasis compared with controls.

Diabetes and related metabolic diseases, such as hyperinsulinemia, insulin resistance, and central obesity, are recognized as major contributors to cardiovascular morbidity and mortality. Psoriasis is known to be associated with several lifestyle factors such as smoking, obesity, and diabetes that per se may increase the risk of cardiovascular morbidity.

5.2 Obesity and diabetes in patients with psoriasis

Psoriasis has a complex relationship with metabolic diseases such as obesity. Studies have shown that, compared with the general population, patients with psoriasis are more frequently overweight (25 ≤ BMI < 30) or obese (BMI > 30).

Adipose tissue, including adipocytes and resident macrophages, may serve as a significant source of TNF-α. TNFα is a pro-inflammatory cytokine that amplifies inflammation through several distinct pathways: facilitating entry of inflammatory cells into the skin through induction of adhesion molecules on vascular endothelial cells; stimulating keratinocyte production of other pro-inflammatory mediators.

Risk for psoriasis has been shown to increase with increasing BMI (P=0.001). This pro-inflammatory state in obesity may explain the association between psoriasis and obesity and these proinflammatory cytokines might also influence the course and presentation of psoriasis. In a study performed by Halla M. Ragab et al., with increase of the severity of the disease, these cytokines are significantly elevated in severe psoriasis patients than in mild to moderate one which is attributed to the role of these cytokines in the pathogenesis and progress of psoriasis and their elevation is responsible for the development, maintenance, and resolution of psoriatic lesions. When patients with psoriasis are more likely to be obese that implies they will also have the comorbid conditions of those with obesity. The risks of diabetes, hypertension, and dyslipidemia start to rise from a BMI of about 21.0 kg/m2 thereby deteriorating the cardiovascular risk profile.

Inflammation plays a role in the pathogenesis of some glucose disorders in adults. Obesity has genetic as well as environmental causes. It has a strong effect on the development of type 2 DM, as it is found in western countries and some ethnic groups such as Pima Indians. Obesity is more than just a risk factor; it has a causal effect in the development of type 2 DM against a genetic background. The evolution from obesity to type DM results from a succession of pathophysiological events: (a) augmentation of the adipose tissue mass, leading to increased lipid oxidation; (b) insulin resistance noted early in obesity, revealed by
euglycemic clamp, as a resistance to insulin mediated glucose storage and oxidation. Blocking the function of the glycogen cycle; (c) despite maintained insulin secretion, unused glycogen prevents further glucose storage leading to type 2 DM; (d) complete b-cell exhaustion appears later.

Also, studies have reported a high prevalence of diabetes among patients with psoriasis. Joshua Barzilay (Tucker, GA) reviewed the association of markers of inflammation with diabetes. Inflammation is strongly related to insulin resistance, although the question of whether treatment directed at the inflammatory process could lead to benefits, such as decreasing the development of diabetes, has yet to be answered. In a study of 200 patients with psoriasis at an Italian clinic reported that 41.5% had diabetes compared with 24.3% of controls (n=280; P<0.001). Of note, 36.7% of psoriasis patients younger than 50 years of age (n=117) had diabetes (P<0.001). Studies have shown that patients with psoriasis have higher rates of impaired glucose tolerance compared with controls (all P<0.05).

5.3 HTA in patients with psoriasis
Several epidemiologic studies have shown that hypertension is a common comorbidity in patients with psoriasis. An increased risk of hypertension of 1.2- to 2-fold has been reported in cross-sectional studies.

As mentioned above, psoriasis is a chronic inflammatory disease, and inflammation is a risk factor for hypertension. Systemic treatments in psoriasis reduce the cardiovascular risk by diminishing the inflammation, but it should be taken into account that most therapies also have adverse cardiovascular effects like dyslipidemia, hyperhomocysteinemia and hypertension.

6. Results of the study
This study covered 599 psoriatic patients (3-80 yrs old) and 599 cases of control group (3-85 yrs old). The age average for both groups varies in 49.64, with a SD value= 19.179 and median value of M=53.00. (Tab.1,2,3)

| Grupi | Frequency | Percent | Valid Percent | Cumulative Percent |
|-------|-----------|---------|---------------|--------------------|
| Valid | Kontroll  | 599     | 50.0          | 50.0               |
|       | Psoriasis | 599     | 50.0          | 100.0              |
|       | Total     | 1198    | 100.0         | 100.0              |

Table 1. Frequency

| Seksi | Frequency | Percent | Valid Percent | Cumulative Percent |
|-------|-----------|---------|---------------|--------------------|
| Valid | M         | 711     | 59.3          | 59.3               |
|       | F         | 487     | 40.7          | 100.0              |
|       | Total     | 1198    | 100.0         | 100.0              |

Table 2. Seksi

The mean glycemia value for both groups was in the value 105.31 with a Standard Deviation value of 38.641 and median value of M= 96.00
Statistics

|        | N  | Mean | Std. Deviation | Std. Error |
|--------|----|------|----------------|------------|
|        | 599| 106.98| 41.700        | 1.704      |
|        | 599| 103.64| 35.275        | 1.441      |

Table 4. Group Statistic

T-Test equality outcome showed that there is no statistical significant difference (considerable) in glycemia values between psoriatic group and control group (P=0.134).

Table 5. Independent Samples Test

7. Discussion

7.1 Are psoriasis and diabetes linked?

Psoriasis and diabetes have a certain common underlying pathogenic mechanisms. Both have an inflammatory nature and both are associated with T-lymphocite –mediated adaptive immune events and mechanisms, involving innate immunity. Specifically, both psoriasis and diabetes are associated with T-helper.

Th-1 inflammatory cytokines such as TNF-α are elevated in the skin and blood of patients with psoriasis and diabetes. Similarly, TNF-α is secreted in adipose tissue and is an important feature of the chronic low level inflammation seen in obesity Insulin resistance, which is common to psoriasis and the metabolic syndrome, may be mediated in part through inflammatory cytokines such as TNF.

The adipocyte is another important component of inflammation. Adipose tissue secrete inflammatory cytokines such as TNF-α and IL-6, and CRP levels increase with increasing
weight. A new concept is that obesity leads to macrophage infiltration of adipose tissues, perhaps because of the action of factors produced by adipocytes themselves, with macrophages rather than adipocytes producing some of the typically measured inflammatory cytokines. In this view, macrophages may produce factors such as TNF-α, causing insulin resistance, while both macrophages and adipocytes produce factors that increase hepatic CRP synthesis, such as IL-6.9 (Table-6). Other cells and biologically active molecules (including cytokines, chemokines, adipokines) that are implicated in the pathogenesis of both psoriasis and diabetes are listed and referenced in Table 6.

A major problem limiting our understanding of the genetic basis of type 2 diabetes is that many environmental and genetically based factors influence insulin sensitivity and insulin secretion: these include age, gender, ethnicity, physical fitness, diet, smoking obesity, and fat distribution.

The prevalence of obesity, diabetes, and metabolic syndrome has been shown to be increased in psoriasis patients in the general population. At least one study has demonstrated a higher prevalence of diabetes in patients who have psoriasis independent of traditional diabetes risk factors such as age, gender, obesity, hypertension, and hyperlipidemia, indicating that the disease itself, or possibly its chronic treatments, may predispose to the development of diabetes.

As early as 1950's, there was epidemiological evidence suggesting a correlation between inflammation and insulin resistant states such as obesity, but the mechanistic links were unknown. In the last decade, however, it has become increasingly evident that obesity and the concomitant development of inflammation are major components of insulin resistance. Studies in human obesity and insulin resistance have revealed a clear association between the chronic activation of pro-inflammatory signaling pathways and decreased insulin sensitivity. For example, elevated levels of tumor necrosis factor-α (TNF), interleukin-6 (IL-6) and interleukin (IL-8) have all been reported in various diabetic and insulin-resistant states. We noticed a non significant difference in the glycemia values of our study of the psoriasis group vs non-psoriasis group. However it has to be pointed out that this study has not taken into consideration other factors like for instance obesity, fat level, HTA which play an important role in insulin resistance. In a cross-sectional study (performed by Reynoso-von Drateln et al.) on lipids profile, insulin secretion and insulin sensitivity at psoriatic patients it resulted that: high-density lipoprotein cholesterol was significantly decreased in patients with psoriasis (p=0.2). There were no significant differences in insulin secretion or sensitivity in patients with psoriasis compared with control patients.

The relationship between systemic treatment of psoriasis and CVR factors has not been adequately studied; however, in rheumatoid arthritis and psoriasis, systemic treatment with methotrexate has been shown to decrease vascular risk. Methotrexate (MTX) is a frequently prescribed agent. MTX blocks DNA synthesis in; rapidly proliferating epidermal cells, T- and B-lymphocytes and disrupts cytokine secretion.

In our psoriasis patient group, the most applied therapy has been the one with Methotrexate and UV phototherapy due to the fact that the psoriasis encountered cases has been between middle and high degree.

UV irradiation induces a degree of systemic immunosuppress mediated via a number of mechanisms possibly including production of Th2 cytokines interleukin(IL-4) and (IL-10). UV-induced vitamin D production may also reduce risks for atherosclerosis in several ways including augmentation of IL-10 and downregulation of TNF-α, C-reactive protein and IL-6 production.
|                     | Psoriasis | Diabetes |
|---------------------|-----------|----------|
| Cytokines           |           |          |
| IL-2                | +         | +        |
| IL-1                | (no)      | +        |
| IL-4                | (no)      | +        |
| IL-5                | (no)      | +        |
| IL-6                | +         | +        |
| IL-10               | (no)      | +        |
| IL-13               | (no)      | +        |
| IL-15               | +         | (no)     |
| IL-17               | +         | (no)     |
| IL-18               | +         | (no)     |
| IL-20               | +         | (no)     |
| IL-23               | +         | (no)     |
| IFN-α               | +         | +        |
| IFN-γ               | +         | +        |
| TNF-α               | +         | +        |
| Chemokines          |           |          |
| IP-10               | +         | +        |
| MCP-1               | +         | +        |
| IL-8                | +         | +        |
| Adipokines          | +         | +        |
| Resistin            | +         | +        |
| Leptin              | +         | +        |
| PAI-1               | +         | +        |
| Adhesion and costimulatory molecules |           |          |
| ICAM/LFA-1          | +         | +        |
| VCAM-1/VLA-4        | +         | +        |
| CD80,CD28           | +         | (no)     |
| CD40/CD40L          | +         | (no)     |
| Leucocytes          |           |          |
| Th1                 | +         | +        |
| Th2                 | +         | +        |
| CD4                 | +         | +        |
| CD8                 | +         | +        |
| Monocytes/Macrophages | +        | +        |
| Neutrophils         | +         | +        |
| Other molecules     |           |          |
| CRP                 | +         | +        |
| iNOS                | +         | +        |
| Oxidized LDL        | +         | +        |

CRP, C-reactive protein; IL interleukin; ICAM, intercellular adhesion molecule; IFN interferon; iNOS, inducible nitric oxide synthase; IP-10, interferon-inducible protein 10; LDL, low density lipoprotein; MCP-1 monocyte chemotactic protein-1; PAI-1 plasminogen activator inhibitor type 1; TNF-α, tumour necrosis factor-alfa; Th1/Th2, T-helper 1 and T-helper 2; VCAM-1, vascular cell adhesion molecule-1

Table 6. Major inflammatory mediators in psoriasis and diabetes
8. Conclusion

Our study is just an observation. Psoriasis is a very complex pathology both from the pathogenesis it provides as well as the ongoing and the complications that could be encountered. Therefore it is more and more necessary to perform studies on it and on the risks it carries on.

9. References

Abel EA, DiCicco LM, Orenberg EK et al. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986;15:1007-22.

Akre O, Granath F, Mallbris L et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225-30.

Alexa Boer Kimball, Ying Wu. Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis. International Journal of Dermatology 2009;48:1147-1156.

Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP. The relation of markers of inflammation to the development of Glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 50:2384-2389, 2001.

Bergmann S, Hanefield M, Henkel E, Jaross W, Koehler C, Siegert G, Temelkova-Kurktschiev T: Subclinical inflammation is strongly related to insulin resistance but not insulin secretion in a high risk population for diabetes. Metabolism 51:743-749, 2002.

Binazzi M, Calandra P, Lisi P. Statistical association between psoriasis and diabetes: further results. Arch Dermatol Res 1975;252:43-48.

Bjorntop P.: Abdominal fat distribution and disease: an overview of epidemiological data. Annals of Medicine, 1992, 24(1): 15-8.

Braun-Falco O, Burg G, Farber EM. Psoriasis. A questionnaire study of 536 patients. Munch Med Wochenschr 1972;114:1105-1110.

Brenelli SL, Moraes AM, Monte-Alegre S, et al. Insulin resistance in psoriasis. Braz J Med Biol Res 1995;28:297-301.

Brown DW, Baker BS, Ovigne JM et al. Skin CD4+ T cells produce interferon-gamma in vitro in response to streptococcal antigens in chronic plaque psoriasis. J Invest Dermatol 2000; 114: 576–80.

Christophers E, Henseler T. Psoriasis type I and type II as subtypes of nonpustular psoriasis. In: Roenigk H, Maibach H, eds. Psoriasis. 2nd ed. New York, NY: Marcel Dekker Inc; 1990:15-21.

Christophers E. Psoriasis epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-20.

Clough R, Rosbotham JL, Trembath RC, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997;6:813–20.

Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008;216:152–5.
Cohen AD, Kagen M, Friger M, Halevy S. Calcium channel blockers intake and psoriasis: a case-control study. Acta Derm Venereol (Stockh) 2001; 81:347-9
Cox N. Polymorphonuclear leukocytes in psoriatic smokers. Br J Dermatol: 121:143,1989
Creamer D, Allen M, Jaggar R, et al. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 2002;138:791-6. Dzienis-Straczkowska S, Kinalska I, Kowalska I, Stepien A, Straczkowska M, Szalachowska M,. Plasma Interleukin-8 Concentrations Are Increased in Obese Subjects and Related to Fat Mass and Tumor Necrosis Factor- [alpha] System. J Clin Endocrinol Metab 2002;87:4602–4606. [PubMed: 12364441]
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428
Elder JT, Nair RP, Guo SW, Henseler T, Christophers E, Voorhees JJ. The genetics of psoriasis. Arch Dermatol. 1994;130:216-224.
Felber JP.; From obesity to diabetes: pathophysiological considerations. International Journal of Obesity, 1992; 16: 937-952.
Feldman S, Margolis J, Nijsten T, Rolstad T, Stern R. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with wide-spread treatment dissatisfaction. J Invest Dermatol 2004; 9:136-9.
Ferrandiz C, Bordas X, Garcia-Patos V, Puig S, Pujol R, Smandia A. Prevalence of psoriasis in Spain (epiderma project: phase I). J Eur Acad Dermatol Venereol 2001;15:20-3
Festa A, D’Agostino R, Howard G, Mykkänen L, Tracey RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 101:42–47, 2000
Fortes C, Mastroeni S, Leffondre K, Sampogna F, Melchi F, Mazzotti E, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005;141:1580-
Fortune DG, Richards HL, Main CJ, Griffiths CE. What patients with psoriasis believe about their condition. J Am Acad Dermatol 1999;39:196-201.
Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W: Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 23:1835–1839, 2000
Gladman DD, Anhorn KA, Schachter RK, et al. HLA antigens in psoriatic arthritis. J Rheumatol1986;13(3):586–92.
Gupta MA, Gupta AK, Wattel GN. Cigarette smoking in men may be a risk factor for increased severity of psoriasis of the extremities. Br J Dermatol: 135:859-60,1996.
Gleison Vieira Duarte et al. Psoriasis and obesity: literature review and recommendation for management. An Bras Dermatol. 2010;85(3):355-60.
Ginsberg HN. Insulin resistance and cardiovascular disease J Clin Invest 2000; 106 :453-458.
Gisondi P, tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol
Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, Chen F, Magliocco M, Krueger JG: TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005, 75:2721-9. 2007;157:68-73.
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41.

Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296:1735–41.

Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296:1735-41.

Giani G, Haastert B, Hanifi-Moghaddam P, Illig T, Koenig W, Kolb H, Martin S, Müller S, Rathmann W, Thorand B. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-α or its receptors. Diabetologia 45:805–812, 2002.

Grosshans E, Lipsker D, Lipsker D, Marquart-Elbaz C. Sartans, angiotensin II receptor antagonists, can induce psoriasis. Br J Dermatol 2002; 147:617-18.

Halla M, Ragab et al. New York Science Journal 2010; 3(10):58-66.

Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32:982-986.

Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13:450-456.

Higgins EM, Peters TJ, du Vivier AW. Smoking, drinking and psoriasis. Br J Dermatol 1993;129:749-50.

Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994;43:1271–1278. [PubMed: 7926300]

Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409–15. [PubMed: 7738205]

Houglwang, Daniel Kess et al. A 9-Centimorgan Interval of Chromosome 10 Controls the T Cell-Dependent Psoriasiform Skin Disease and Arthritis in a Murine Psoriasis Model. The Journal of Immunology 2008, 180, 5520-5527.

Hussain I, Haroon TS. Comorbidities in psoriasis and their therapeutic implications. J Pak Assoc Dermatol 2009; 19: 63-5.

James T et al. The genetic of psoriasis 2001. Arch Dermatol. 2001; 137: 1447-1454

James WPT, Jackson-Leach R, Ni Mhurchu C, et al. Overweight and obesity (high body mass index). In: Ezzati M, Lopez AD, Rodgers A, Murray CJL, editors. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors, vol. 1. Geneva:WHO; 2004. p. 497–596.

Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976;38:46–51.

Kaprio J, Tuomilehto Koskenvuo M et al.; Concordance for Type 1 (insulindependent) and Type 2 (non-insulin-dependent) diabetes mellitus in population based cohort of twins in Finland. Diabetesologia, 1992; 35: 1060-1067.

Kinya-I-Asadi A, Usman A. The role of psychological stress in skin disease. J Cutan Med Surg 2001; 5:140-145.

Knowler WC, Pettitte DJ, Saad MF et al.; Obesity in the Pima Indians: its magnitude and relationship with diabetes. Am. J. Clin. Nutr., 1991; 53: 1543-1551.
Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485-96.

Lee E, TW, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199(1):125–30.

Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, et al. Psoriasis: A possible risk factor for development of coronary artery calcification. Br J Dermatol 2007;156:271-6.

Mallbris L, Ritchlin CT, Stahle m. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2006; 8: 355-363.

McKeigue PM, Pierpoint T, Ferrie VE and Marmot MG.; Relationship of glucose intolerance and hyperinsulinaemia to body fat pattern in south Asians and Europeans. Diabetologia. 1992; 35(8): 785-91.

M Berg, M Svensson et al. Psoriasis and stress: A prospective study. JEADV 2008, 22, 670-674.

Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125:61-7.

Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125:61-67.

Neumann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55(5): 829–35.

Nickoloff BJ, Schroder JM, von den Driesch P, et al. Is psoriasis a T-cell disease? Exp Dermatol. 2000; 9: 359-375.

O’Brien M, Koo J. The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol 2006; 5: 426-32.

Ovigne JM, Baker BS, Davison SC et al. Epidermal CD8+ T cells reactive with group A streptococcal antigens in chronic plaque psoriasis. Exp Dermatol 2002; 11: 357–64.

Owerbach D, Lernmark A, Pleath P et al.; HLA-D region b-chain DNA endonuclease fragments differ between HLA-DR identical healthy and insulin dependent diabetic individuals. Nature, 1983; 303: 815-817.

Poikolainen K, Reunala T, Karvon J, Lauharanta J, Karkkainen P. Alcohol intake: A risk factor for psoriasis in young and iddle aged men? BMJ 1990;300:780-3.

Poikolainen K, Reunala T, Karvon J. Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol 1994; 130:473-7.

Poikolainen K, Karvon J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999; 135:1490-3.

Poikolainen K, Karvon J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch dermatol; 135: 1490-3, 1999.

Perarce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatol Treat 2005; 16:319-323.

Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 64(Suppl 2): 37–9.

Raychaudhuri L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125:61-7.
Psoriasis and Diabetes

Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz BR, et al. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol, 2003;48:882-885

Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115-126

Roytblat L, Rachinsky M, Fisher A, Greenberg L, Shapiro Y, Douvdevani A, Gelman S. Raised Interleukin-6 Levels in Obese Patients. Obes Res 2000;8:673–675. [PubMed: 11225716]

Russell TJ, Schultes LM, Kuban DJ. Histocompatibility (HLA) antigens associated with psoriasis. N Engl J Med. 1972;287:738-740

Russo PA, Ilchev R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol 2004;45:155-9; quiz 60-1.

Schon MP, Boehncke WH. Psoriasis. N Engl J Med; 352: 1899-912, 2005

Sander HM, Morris LF, Phillips CM, Harrison PE, Menter A. The annual cost of psoriasis. J Am Acad Dermatol. 1993;28:422-425.

Stephen K. Richardson, Joel M. Gelfand. Update of the natural history and systemic treatment of psoriasis. Advances in Dermatology. 24(2008)171-196

Seckin D, Tokgozoglu L, Akkaya S. Are lipoprotein profile and lipoprotein (a) levels altered in men with psoriasis? J Am Acad Dermatol 1994;31:445-449

Sakkinen PA, Wahl P, Cushen M, Lewis MR, Tracey RP. Clustering of procoagulation, inflammation and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 152:897–907, 2000.

Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Int Med 2007;167:1670–1675.

Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. PNAS 2003;100:7265–7270. [PubMed: 12756299]

Targher G, Alberiche M, Zenere M, Bonadonna R, Muggeo M, Bonora E. 1997 Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:3619–3624

Ullrich SE. Mechanisms underlying UV-induced immune suppression. Mutat Res 2005;571:185-205

Valdimarsson H. The genetic basis of psoriasis. Clin Dermatol 2007;25(6):563–7.

Villeda-Gabriel G et al. The recognition of streptococcus pyogenes and skin autoantigens in guttate psoriasis: Arch Med Res.1998 Summer;29(2): 143-8.

Zimmerman GM. Alcohol and psoriasis: a double burden. Arch Dermatol 1999;135:1541–1542.

Yki-Järvinen H. 1995 Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia 38:1378–1388

Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2007;190(1):1-9.

Wang F LE, Lowes MA, Haider AS, et al. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: gene regulation and cellular effect. J Invest Dermatol2006;2006(7):1590-9.

Wang TJ, Pencina MJ, Booth SL et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008: 117:503-11.
Wassmuth R and Lernmark A.; The genetics of susceptibility to diabetes. Clin. Immunol. Immunopathol, 1989; 53: 358-399.
Wellen KE, Hotamisligil GS: Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112:1785–1788, 2003
Wilkin J. Exacerbation of psoriasis during clonidine therapy. Arch Dermatol 1981; 117:4.
This book is a collection of comprehensive reviews contributed by experts in the diverse fields of acute and chronic inflammatory diseases, with emphasis on current pharmacological and diagnostic options. Interested professionals are also encouraged to review the contributions made by experts in a second related book entitled "Inflammation, Chronic Diseases and Cancer"; it deals with immunobiology, clinical reviews, and perspectives of the mechanisms of immune inflammatory responses that are involved in alterations of immune dynamics during the genesis, progression and manifestation of a number of inflammatory diseases and cancers, as well as perspectives for diagnosis, and treatment or prevention of these disabling and potentially preventable diseases, particularly for the growing population of older adults around the globe.

**How to reference**
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Ermira Vasili, Migena Vargu, Genc Burazeri, Katerina Hysa, Elna Cano and Brikena Bezati (2012). Psoriasis and Diabetes, Inflammatory Diseases - Immunopathology, Clinical and Pharmacological Bases, Dr Mahin Khatami (Ed.), ISBN: 978-953-307-911-0, InTech, Available from: http://www.intechopen.com/books/inflammatory-diseases-immunopathology-clinical-and-pharmacological-bases/psoriasis-and-diabetes